NL-OMON33125已完成不适用
A first in human sequential dose-escalation study investigating safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of NS11821 in healthy male subjects - NS11821 First In Man Study
eurosearch0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Voluntary provision of written informed consent prior to any study procedure, indicative of understanding the purpose of the study and willing to participate in the study and comply with the study procedures and restrictions.
- •3. Aged 18-45 years (both inclusive).
排除标准
- •1. Subject is unhealthy according to medical history, physical examination, ECG, blood pressure and heart rate, and laboratory profile of blood and urine. A volunteer with a clinical abnormality may be included only if the investigator or his designee considers that the abnormality will not introduce additional risk factor for the subject's health, or interfere with the study objectives.
- •2. Presence or history of clinical significant psychiatric diseases, as judged by the investigator.
- •3. Any clinically relevant acute or chronic diseases which according to the investigator could interfere with the subject*s safety during the trial, or expose them to undue risk, or which could interfere with the study objectives.
- •4. Presence or history of clinical significant diseases of the renal, hepatic, gastrointestinal, cardiovascular, musculoskeletal system or presence of history of clinical significant immunological, endocrine, metabolic diseases, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, as judged by the investigator.
- •5. Presence or history of clinically significant allergy or known hypersensitivity to any component of the investigational product.
- •6. Has a Body Mass Index (BMI) < 18 or > 30 kg/m2.
- •7. Has positive serology for HIV-1, HIV-2, hepatitis B (surface antigen), and/or hepatitis C.
- •8. Has planned medical treatments (including dental care) from screening to follow-up visit.
- •9. Use of prescribed medication or over-the-counter (OTC) medication within two weeks prior to dosing, except for paracetamol.
- •C HDR Protocol CHDR0907 NS11821 First In Man Study
- •C:\Documents and Settings\Default.WSIMAGE.001\Desktop\CHDR0907_pro_00.doc - 22-06-2009 Page 20 of 142
- •10. Enrolment in any investigational study or intake of an investigational drug within 3 months prior to the start of the study or more than 4 times a year.
- •11. Current regular user of any illicit drugs or history of drug or alcohol abuse. Subjects who have a positive drug screen at screening and/or pre-dose or subjects who have a positive alcohol breath test at pre-dose will be excluded.
- •12. Donation of blood/plasma outside limits of Sanquin Blood Supply Foundation guidelines.
- •13. Previous randomization in this study.
- •14. Has any barrier (language, mental incapacity, etc.) that could interfere with the psychomotor or cognitive tests.
- •15. Unlikely to co-operate in the study, and/or has poor compliance anticipated by the investigator. Or not consistently reachable in case of emergency.
- •16. Daily consumption of xanthine-containing products more than 6 units. Unwilling or unable to refrain from consumption of xanthine-containing foods or drinks from 2 days prior to admission and during the stay in the research unit. One caffeine unit is contained in the following items: one cup of coffee, two cans of cola, one glass of tea, * cup of energy drink (e.g. Red Bull) or three chocolate bars.
- •17. Unwilling or unable to refrain from intensive physical exercise from screening until the follow-up visit.
- •18. Unwilling or unable to refrain from products containing alcohol from 2 days before admission and during the stay in the research unit.
- •19. Unwilling or unable to refrain from products containing grapefruit from 2 days before admission and during the stay in the research unit.
- •20. Smokes more than 5 cigarettes (or equivalent as judged by the investigator) a
研究者
相似试验
进行中（未招募）
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CTIS2023-504403-92-00Janssen - Cilag International200
招募中
不适用
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)LeukemiaNL-OMON55976Biomea Fusion Inc.12
尚未招募
不适用
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myelomamultiple myelomaNL-OMON53500Janssen-Cilag12
已完成
不适用
A Phase 1 first- in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally as monotherapy and in combination with cemiplimab in patients with advanced solid tumorsAdvanced solid tumors10027655NL-OMON55221Genzyme Europe BV11
已完成
不适用
A First in Human, Single-dose Escalation Study of LY2562175 In Healthy Subjectslipidsmetabolism10013317NL-OMON33901Chorus, Lilly Research Laboratories18